Compare AstraZeneca plc (AZN) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? AstraZeneca plc trades at $168.06 (market cap $253.13B), while JPMorgan Diversified Return International Eqty ETF trades at $73.33. The key difference: AstraZeneca plc pays a 1.92% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | JPIN | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | — |
52-Week High | $209.48 | $76.96 |
52-Week Low | $137.44 | $63.14 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
JPIN trades at $72.785, down 0.78% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance near $73 and support at $72. Recent corporate actions include a declared dividend of $0.91 scheduled for June 2026. Market sentiment remains mixed, with oscillators neutral and moving averages signaling bearish pressure.
The outlook for JPIN is cautious due to weak technical momentum and limited fundamental data availability. Key risks include market volatility and reliance on international equity performance. Investors should monitor upcoming financial disclosures for clarity on valuation and profitability metrics to assess long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
